S&P 500   4,088.85
DOW   32,654.59
QQQ   306.17
S&P 500   4,088.85
DOW   32,654.59
QQQ   306.17
S&P 500   4,088.85
DOW   32,654.59
QQQ   306.17
S&P 500   4,088.85
DOW   32,654.59
QQQ   306.17
NASDAQ:RETA

Reata Pharmaceuticals (RETA) Stock Forecast, Price & News

$27.84
+2.57 (+10.17%)
(As of 05/17/2022 04:00 PM ET)
Add
Compare
Today's Range
$25.46
$28.88
50-Day Range
$20.71
$39.60
52-Week Range
$20.24
$153.41
Volume
523,825 shs
Average Volume
662,773 shs
Market Capitalization
$1.01 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.25
30 days | 90 days | 365 days | Advanced Chart
Receive RETA News and Ratings via Email

Sign-up to receive the latest news and ratings for Reata Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Reata Pharmaceuticals logo

About Reata Pharmaceuticals

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase 2 study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and RTA 1701 for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of autosomal dominant polycystic kidney disease. Further, it has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.

Headlines

Recap: Reata Pharmaceuticals Q4 Earnings
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RETA
Fax
N/A
Employees
346
Year Founded
N/A

Sales & Book Value

Annual Sales
$11.49 million
Book Value
$5.11 per share

Profitability

Net Income
$-297.39 million
Net Margins
-2,650.72%
Pretax Margin
-2,654.25%

Debt

Price-To-Earnings

Miscellaneous

Free Float
26,211,000
Market Cap
$1.01 billion
Optionable
Optionable

Company Calendar

Last Earnings
5/10/2022
Today
5/17/2022
Next Earnings (Estimated)
8/08/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.36 out of 5 stars

Medical Sector

216th out of 1,426 stocks

Pharmaceutical Preparations Industry

81st out of 680 stocks

Analyst Opinion: 3.3Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -













Reata Pharmaceuticals (NASDAQ:RETA) Frequently Asked Questions

Is Reata Pharmaceuticals a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Reata Pharmaceuticals in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Reata Pharmaceuticals stock.
View analyst ratings for Reata Pharmaceuticals
or view top-rated stocks.

When is Reata Pharmaceuticals' next earnings date?

Reata Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Reata Pharmaceuticals
.

How were Reata Pharmaceuticals' earnings last quarter?

Reata Pharmaceuticals, Inc. (NASDAQ:RETA) posted its quarterly earnings results on Tuesday, May, 10th. The company reported ($2.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.26) by $0.23. The business earned $0.91 million during the quarter, compared to the consensus estimate of $1.55 million. Reata Pharmaceuticals had a negative trailing twelve-month return on equity of 137.52% and a negative net margin of 2,650.72%. The company's quarterly revenue was down 3.2% on a year-over-year basis. During the same period last year, the business earned ($1.86) EPS.
View Reata Pharmaceuticals' earnings history
.

What price target have analysts set for RETA?

6 brokerages have issued 12-month target prices for Reata Pharmaceuticals' stock. Their forecasts range from $35.00 to $244.00. On average, they expect Reata Pharmaceuticals' share price to reach $89.86 in the next twelve months. This suggests a possible upside of 222.8% from the stock's current price.
View analysts' price targets for Reata Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Reata Pharmaceuticals' key executives?
Reata Pharmaceuticals' management team includes the following people:
  • Mr. J. Warren Huff, Chairman & CEO (Age 68, Pay $1.06M)
  • Mr. Manmeet Singh Soni, COO, CFO & Pres (Age 44, Pay $1.13M)
  • Mr. Michael D. Wortley, Exec. VP & Chief Legal Officer (Age 74, Pay $760.6k)
  • Dr. Colin J. Meyer M.D., Exec. VP & Chief Innovation Officer (Age 43, Pay $895.35k)
  • Ms. Dawn Carter Bir, Exec. VP & Chief Commercial Officer (Age 51, Pay $666.9k)
  • Mr. Bhaskar Anand, VP & Chief Accounting Officer (Age 45)
  • Mr. Kevin A. Johnston, VP & Chief Technical Officer
  • Dr. W. Christian Wigley Ph.D., Sr. VP & Chief Scientific Officer
  • Mr. Dakota Gallivan, VP & Chief Healthcare Compliance Officer
  • Mr. Steve Harman, Sr. VP & Chief HR Officer
What is Warren Huff's approval rating as Reata Pharmaceuticals' CEO?

10 employees have rated Reata Pharmaceuticals CEO Warren Huff on Glassdoor.com. Warren Huff has an approval rating of 92% among Reata Pharmaceuticals' employees. This puts Warren Huff in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Reata Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Reata Pharmaceuticals investors own include Approach Resources (AREX), Precision Drilling (PDS), First Financial Bankshares (FFIN), Synlogic (SYBX), NVIDIA (NVDA), Basic Energy Services (BAS), Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO) and Archrock (AROC).

When did Reata Pharmaceuticals IPO?

(RETA) raised $60 million in an IPO on Thursday, May 26th 2016. The company issued 4,000,000 shares at $14.00-$16.00 per share. Citigroup, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO.

What is Reata Pharmaceuticals' stock symbol?

Reata Pharmaceuticals trades on the NASDAQ under the ticker symbol "RETA."

Who are Reata Pharmaceuticals' major shareholders?

Reata Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Wellington Management Group LLP (12.08%), Vanguard Group Inc. (7.26%), BlackRock Inc. (5.70%), State Street Corp (1.84%), Emerald Advisers LLC (0.74%) and Northern Trust Corp (0.74%). Company insiders that own Reata Pharmaceuticals stock include Colin John Meyer, Elaine Castellanos, James Warren Huff and Michael D Wortley.
View institutional ownership trends for Reata Pharmaceuticals
.

Which institutional investors are selling Reata Pharmaceuticals stock?

RETA stock was sold by a variety of institutional investors in the last quarter, including Invesco Ltd., Goldman Sachs Group Inc., Integral Health Asset Management LLC, BlackRock Inc., TD Asset Management Inc., MADDEN SECURITIES Corp, King Luther Capital Management Corp, and Northern Trust Corp. Company insiders that have sold Reata Pharmaceuticals company stock in the last year include Colin John Meyer, and Elaine Castellanos.
View insider buying and selling activity for Reata Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Reata Pharmaceuticals stock?

RETA stock was acquired by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Simplex Trading LLC, Emerald Advisers LLC, Vanguard Group Inc., Verition Fund Management LLC, Graham Capital Management L.P., Jane Street Group LLC, and Emerald Mutual Fund Advisers Trust.
View insider buying and selling activity for Reata Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Reata Pharmaceuticals?

Shares of RETA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Reata Pharmaceuticals' stock price today?

One share of RETA stock can currently be purchased for approximately $27.84.

How much money does Reata Pharmaceuticals make?

Reata Pharmaceuticals has a market capitalization of $1.01 billion and generates $11.49 million in revenue each year. The company earns $-297.39 million in net income (profit) each year or ($8.350010) on an earnings per share basis.

How many employees does Reata Pharmaceuticals have?

Reata Pharmaceuticals employs 346 workers across the globe.

What is Reata Pharmaceuticals' official website?

The official website for Reata Pharmaceuticals is www.reatapharma.com.

How can I contact Reata Pharmaceuticals?

Reata Pharmaceuticals' mailing address is 5320 LEGACY DRIVE, PLANO TX, 75024. The company can be reached via phone at (972) 865-2219 or via email at [email protected].

This page was last updated on 5/18/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.